Sparsentan: Difference between revisions
Content deleted Content added
add first-in-class |
infobox |
||
| Line 11: | Line 11: | ||
| pronounce = |
| pronounce = |
||
| tradename = Filspari |
| tradename = Filspari |
||
| Drugs.com = {{drugs.com| |
| Drugs.com = {{drugs.com|monograph|sparsentan}} |
||
| MedlinePlus = |
| MedlinePlus = a623018 |
||
| DailyMedID = Sparsentan |
| DailyMedID = Sparsentan |
||
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X --> |
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X --> |
||
| Line 56: | Line 56: | ||
<!-- Identifiers --> |
<!-- Identifiers --> |
||
| CAS_number = |
| CAS_number = 254740-64-2 |
||
| CAS_supplemental = |
| CAS_supplemental = |
||
| PubChem = |
| PubChem = |
||
| IUPHAR_ligand = |
| IUPHAR_ligand = |
||
| DrugBank = |
| DrugBank = DB12548 |
||
| ChemSpiderID = |
| ChemSpiderID = |
||
| UNII = |
| UNII = 9242RO5URM |
||
| KEGG = D11776 |
| KEGG = D11776 |
||
| ChEBI = |
| ChEBI = |
||
| Line 78: | Line 78: | ||
| molecular_weight = |
| molecular_weight = |
||
| molecular_weight_comment = |
| molecular_weight_comment = |
||
| SMILES = |
| SMILES = CCCCC1=NC2(CCCC2)C(=O)N1CC1=CC=C(C(COCC)=C1)C1=CC=CC=C1S(=O)(=O)NC1=NOC(C)=C1C |
||
| StdInChI = 1S/C32H40N4O5S/c1-5-7-14-29-33-32(17-10-11-18-32)31(37)36(29)20-24-15-16-26(25(19-24)21-40-6-2)27-12-8-9-13-28(27)42(38,39)35-30-22(3)23(4)41-34-30/h8-9,12-13,15-16,19H,5-7,10-11,14,17-18,20-21H2,1-4H3,(H,34,35) |
|||
| StdInChI = |
|||
| StdInChI_comment = |
| StdInChI_comment = |
||
| StdInChIKey = |
| StdInChIKey = WRFHGDPIDHPWIQ-UHFFFAOYSA-N |
||
| density = |
| density = |
||
| density_notes = |
| density_notes = |
||
Revision as of 04:50, 10 January 2024
 | |
| Clinical data | |
|---|---|
| Trade names | Filspari |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a623018 |
| License data |
|
| Routes of administration | By mouth |
| ATC code |
|
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| DrugBank | |
| UNII | |
| KEGG | |
| Chemical and physical data | |
| 3D model (JSmol) | |
| |
| |
Sparsentan, sold under the brand name Filspari, is a medication used for the treatment of primary immunoglobulin A nephropathy.[1] Sparsentan is an endothelin and angiotensin II receptor antagonist.[1][2]
It was approved for medical use in the United States in February 2023.[1][3][4] The US Food and Drug Administration (FDA) considers it to be a first-in-class medication.[5]
Medical uses
Sparsentan is indicated to reduce proteinuria in people with primary immunoglobulin A nephropathy.[1]
Society and culture
Legal status
Sparsentan is approved in the US under accelerated approval based on reduction of proteinuria.[1]
References
- ^ a b c d e f "Filspari- sparsentan tablet, film coated". DailyMed. 17 February 2023. Retrieved 6 March 2023.
- ^ Chiu AW, Bredenkamp N (September 2023). "Sparsentan: A First-in-Class Dual Endothelin and Angiotensin II Receptor Antagonist". The Annals of Pharmacotherapy: 10600280231198925. doi:10.1177/10600280231198925. PMID 37706310. S2CID 261743204.
- ^ "Travere Therapeutics Announces FDA Accelerated Approval of Filspari (sparsentan), the First and Only Non-immunosuppressive Therapy for the Reduction of Proteinuria in IgA Nephropathy" (Press release). Travere Therapeutics. 17 February 2023. Retrieved 17 February 2023 – via GlobeNewswire.
- ^ Syed YY (April 2023). "Sparsentan: First Approval". Drugs. 83 (6): 563–568. doi:10.1007/s40265-023-01864-x. PMC 10232600. PMID 37022667.
- ^ New Drug Therapy Approvals 2023 (PDF). U.S. Food and Drug Administration (FDA) (Report). January 2024. Archived from the original on 10 January 2024. Retrieved 9 January 2024.
External links
- Clinical trial number NCT03762850 for "A Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA Nephropathy (PROTECT)" at ClinicalTrials.gov
 | This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |